ACHFF Stock — Arch Biopartners Inc

Arch Biopartners Inc (ACHFF)

Updated October 16, 2026.

ACHFF is a Stock. Total return is 1078.7% over the past 24.5 years, 91.3 points ahead of SPY at 987.4%.

Arch Biopartners is a Canadian biopharmaceutical company developing novel drugs for acute kidney injury and organ damage, with its lead candidate in Phase 2 trials for treating inflammation-related kidney injury in cardiac surgery patients, alongside programs targeting chronic kidney disease. The company does not currently pay distributions. This security appeals primarily to investors with risk tolerance for early-stage drug development and exposure to the healthcare sector.

ACHFF performance versus SPY

Price and return data through 2026-10-16.

Total return is 1078.7% over the past 24.5 years, 91.3 points ahead of SPY at 987.4%. Over the past year its total return — price change plus distributions reinvested — is -19.5%. Its deepest 1-year drawdown was 69.9%.

ACHFF key facts

Asset type

Stock

Asset class

Equity

Inception date

04/24/2002

Distribution frequency

None

Last close

$0.56 (as of 2026-10-16)

Market cap

$38,035,849

Average volume

13601.0

Beta

1.804

Payout ratio

0.0%

EPS

$-0.04

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ACHFF risks and drawbacks

The deepest 1-year drawdown on record here is 69.9%.

Who may consider ACHFF — and who may not

It is a weaker fit for investors who need monthly cash flow (ACHFF does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ACHFF

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions